Guggenheim Reiterates “Buy” Rating for Larimar Therapeutics (NASDAQ:LRMR)
Guggenheim reaffirmed their buy rating on shares of Larimar Therapeutics (NASDAQ:LRMR – Free Report) in a report published on Tuesday morning,Benzinga reports. The brokerage currently has a $26.00 price objective on the stock. Several other equities research analysts have also commented on LRMR. Robert W. Baird decreased their price objective on shares of Larimar Therapeutics […]
Guggenheim reaffirmed their buy rating on shares of Larimar Therapeutics (NASDAQ:LRMR – Free Report) in a report published on Tuesday morning,Benzinga reports. The brokerage currently has a $26.00 price objective on the stock. Several other equities research analysts have also commented on LRMR. Robert W. Baird decreased their price objective on shares of Larimar Therapeutics […]
